Abstract

Glucocorticoids are among the most frequently used anti-inflammatory and immunosuppressive drugs. They are widely used in the treatment of numerous autoimmune disorders. However, the treatment with glucocorticoids is connected with the risk of a number of side effects. Among them, glucose tolerance disorders play an important role. The results of meta-analyses show that the risk of diabetes is from 1.4 to 2.5 times higher in the case of treated patients in comparison to the general population. Glucocorticoids can directly impair pancreatic β-cell secretion. Nevertheless, a crucial role in the hyperglycemic activity seems to be played by a peripheral glucose uptake reduction, principally in the skeletal muscle, which is responsible for the decrease of insulin sensitivity, and can manifest itself in the increase of postprandial blood glucose levels. If they are used in higher doses and for a prolonged period, they can also reduce the inhibitory effect of insulin on hepatic glucose production, which can lead to an increase of fasting plasma glucose. Numerous literature data indicate that in the case of patients who suffer from inflammatory diseases of the musculoskeletal system, the treatment with low to moderate doses of glucocorticoids, for a short period, does not significantly increase the metabolic risk. The beneficial role in this area may be connected with an anti-inflammatory and immunosuppressive effect. The regular assessment of the postprandial glucose, especially in the afternoon and evening, has the highest diagnostic sensitivity of glucocorticoid-induced glucose tolerance disorders. In the case of patients without a prior diagnosis of diabetes, after discontinuation of treatment, the oral glucose tolerance test should be considered in order to identify the presence of persistent disorders.

References

• 1. Bertsias G., Ioannidis J.P., Boletis J., Bombardieri S., Cervera R.,Dostal C., Font J., Gilboe I.M., Houssiau F., Huizinga T., Isenberg D.,Kallenberg C.G., Khamashta M.,Piette J.C., Schneider M. i wsp.: EULARrecommendations for the management of systemic lupus erythematosus.Report of a Task Force of the EULAR Standing Committee forInternational Clinical Studies Including Therapeutics. Ann. Rheum.Dis., 2008; 67: 195-205
  Google Scholar
• 2. Blackburn D., Hux J., Mamdani M.: Quantification of the risk ofcorticosteroid-induced diabetes mellitus among the elderly. J. Gen.Intern. Med., 2002; 17: 717-720
  Google Scholar
• 3. Boyer J.F., Gourraud P.A, Cantagrel A., Davignon J.L., ConstantinA.: Traditional cardiovascular risk factors in rheumatoid arthritis:a meta-analysis. Joint Bone Spine, 2011; 78: 179-183
  Google Scholar
• 4. Bremander A., Petersson I.F., Bergman S., Englund M.: Populationbasedestimates of common comorbidities and cardiovascular diseasein ankylosing spondylitis. Arthritis Care Res., 2011; 63: 550-556
  Google Scholar
• 5. Bruno A., Pagano G., Benzi L., Di Ciani G., Spallone V., CalabreseG., Passeri A.: Change in glucose metabolism after long-term treatmentwith deflazacort and betamethasone. Eur. J. Clin. Pharmacol.,1992; 43: 47-50
  Google Scholar
• 6. Burt M.G., Roberts G.W., Aguilar-Loza N.R., Frith P., Stranks S.N.:Continuous monitoring of circadian glycemic patterns in patientsreceiving prednisolone for COPD. J. Clin. Endocrinol. Metab., 2011;96: 1789-1796
  Google Scholar
• 7. Burt M.G., Willenberg V.M., Petersons C.J.,Smith M.D., AhernM.J., Stranks S.N.: Screening for diabetes in patients with inflammatoryrheumatological disease administered long-term prednisolone:a cross-sectional study. Rheumatology, 2012; 51: 1112-1119
  Google Scholar
• 8. Buttgereit F., da Silva J.A., Boers M., Burmester G.R., Cutolo M.,Jacobs J., Kirwan J., Köhler L., Van Riel P., Vischer T., Bijlsma J.W.:Standardised nomenclature for glucocorticoid dosages and glucocorticoidtreatment regimens: current questions and tentative answersin rheumatology. Ann. Rheum. Dis., 2002; 61: 718-722
  Google Scholar
• 9. Chen H.H., Yeh S.Y., Chen H.Y., Lin C.L., Sung F.C., Kao C.H.: Ankylosingspondylitis and other inflammatory spondyloarthritis increasethe risk of developing type 2 diabetes in an Asian population.Rheumatol. Int., 2014; 34: 265-270
  Google Scholar
• 10. Chen Y.M., Lin C.H., Lan T.H., Chen H.H., Chang S.N., Chen Y.H.,Wang J.S., Hung W.T., Lan J.L., Chen D.Y.: Hydroxychloroquine reducesrisk of incident diabetes mellitus in lupus patients in a dosedependentmanner: a population-based cohort study. Rheumatology,2015; 54: 1244-1249
  Google Scholar
• 11. Clore J.N., Thurby-Hay L.: Glucocorticoid-induced hyperglycemia.Endocr. Pract., 2009; 15: 469-474
  Google Scholar
• 12. Dasgupta B., Dolan A.L., Panayi G.S., Fernandes L.: An initiallydouble-blind controlled 96 week trial of depot methylprednisoloneagainst oral prednisolone in the treatment of polymyalgia rheumatica.Br. J. Rheumatol., 1998; 37: 189-195
  Google Scholar
• 13. Davis J.M., Maradit Kremers H., Crowson C.S. Nicola P.J., BallmanK.V., Therneau T.M., Roger V.L., Gabriel S.E.: Glucocorticoids andcardiovascular events in rheumatoid arthritis: a population-basedcohort study. Arthritis Rheum., 2007; 56: 820-830
  Google Scholar
• 14. Dąbrowski P.: Występowanie zaburzeń tolerancji glukozy i insulinoopornościu chorych na reumatoidalne zapalenie stawów orazzesztywniające zapalenie stawów kręgosłupa w odniesieniu do aktywnościchoroby oraz stosowanego leczenia. Praca Doktorska. UniwersytetMedyczny w Lublinie. 25.06.2015
  Google Scholar
• 15. Dąbrowski P., Majdan M.: Insulin resistance and metabolic syndrome– a different image of disorders in rheumatoid arthritis andankylosing spondylitis. Wiad. Lek., 2015; 68: 235-241
  Google Scholar
• 16. Dejaco C., Singh Y.P., Perel P., Hutchings A., Camellino D., MackieS., Matteson E.L., Dasgupta B.: Current evidence for therapeuticinterventions and prognostic factors in polymyalgia rheumatica:a systematic literature review informing the 2015 European LeagueAgainst Rheumatism/American College of Rheumatology recommendationsfor the management of polymyalgia rheumatica. Ann.Rheum. Dis., 2015; 74: 1808-1817
  Google Scholar
• 17. Dessein P.H., Joffe B.I., Stanwix A.E., Christian BF, Veller M.:Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J.Rheumatol., 2004; 31: 867-874
  Google Scholar
• 18. Duru N., van der Goes M.C., Jacobs J.W., Andrews T., Boers M.,Buttgereit F., Caeyers N., Cutolo M., Halliday S., Da Silva J.A., KirwanJ.R., Ray D., Rovensky J.,Severijns G., Westhovens R., Bijlsma J.W.:EULAR evidence-based and consensus-based recommendations onthe management of medium to high-dose glucocorticoid therapy inrheumatic diseases. Ann. Rheum. Dis., 2013; 72: 1905-1913
  Google Scholar
• 19. Fong A.C., Cheung N.W.: The high incidence of steroid-inducedhyperglycaemia in hospital. Diabetes Res. Clin. Pract., 2013; 99: 277-280
  Google Scholar
• 20. Gonzalez-Gonzalez J.G., Mireles-Zavala L.G., Rodriguez-GutierrezR., Gomez-Almaguer D., Lavalle-Gonzalez F.J., Tamez-Perez H.E.,Gonzalez-Saldivar G.,Villarreal-Perez J.Z.: Hyperglycemia related tohigh-dose glucocorticoid use in noncritically ill patients. Diabetol.Metab. Syndr., 2013; 5: 18
  Google Scholar
• 21. Gulliford M.C., Charlton J., Latinovic R.: Risk of diabetes associatedwith prescribed glucocorticoids in a large population. DiabetesCare, 2006; 29: 2728-2729
  Google Scholar
• 22. Gurwitz J.H., Bohn R.L., Glynn R.J., Monane M., Mogun H., AvornJ.: Glucocorticoids and the risk for initiation of hypoglycemic therapy.Arch. Intern. Med., 1994; 154: 97-101
  Google Scholar
• 23. Ha Y., Lee K.H., Jung S., Lee S.W., Lee S.K., Park Y.B.: Glucocorticoid-induceddiabetes mellitus in patients with systemic lupuserythematosus treated with high-dose glucocorticoid therapy. Lupus,2011; 20: 1027-1034
  Google Scholar
• 24. Han C., Robinson D.W.Jr., Hackett M.V., Paramore L.C., FraemanK.H., Bala M.V.: Cardiovascular disease and risk factors in patientswith rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.J. Rheumatol., 2006; 33: 2167-2172
  Google Scholar
• 25. Hällgren R., Berne C.: Glucose intolerance in patients withchronic inflammatory diseases is normalized by glucocorticoids.Acta Med. Scand., 1983; 213: 351-355
  Google Scholar
• 26. Holle J.U., Bley T., Gross W.L.: Classification and therapy of vasculitisaccording to recommendations of the European League AgainstRheumatism (EULAR). Radiologe, 2010; 50: 846-854
  Google Scholar
• 27. Hwang J.L., Weiss R.E.: Steroid-induced diabetes: a clinical andmolecular approach to understanding and treatment. DiabetesMetab. Res. Rev., 2014; 30: 96-102
  Google Scholar
• 28. Katsuyama T., Sada K.E., Namba S., Watanabe H., Katsuyama E.,Yamanari T., Wada J., Makino H.: Risk factors for the development ofglucocorticoid-induced diabetes mellitus. Diabetes Res. Clin. Pract.,2015; 108: 273-279
  Google Scholar
• 29. Kim S.Y., Yoo C.G., Lee C.T., Chung H.S., Kim Y.W., Han S.K., ShimY.S., Yim J.J.: Incidence and risk factors of steroid-induced diabetesin patients with respiratory disease. J. Korean Med. Sci., 2011; 26:264-267
  Google Scholar
• 30. Koppe L., Pelletier C.C., Alix P.M., Kalbacher E., Fouque D., SoulageC.O., Guebre-Egziabher F.: Insulin resistance in chronic kidneydisease: new lessons from experimental models. Nephrol. Dial.Transplant., 2014; 29: 1666-1674
  Google Scholar
• 31. Liu D., Ahmet A., Ward L., Krishnamoorthy P., Mandelcorn E.D.,Leigh R., Brown J.P., Cohen A., Kim H.: A practical guide to the monitoringand management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol., 2013; 9: 30
  Google Scholar
• 32. Movahedi M., Lunt M., Ray D., Dixon W.: Oral glucocorticoidsand the risk of incident type 2 Diabetes mellitus in patients withrheumatoid arthritis, a retrospective cohort study. Ann. Rheum.Dis., 2013; 72, Supp. 3: A239-A240
  Google Scholar
• 33. Nagalski A., Kiersztan A.: Physiology and molecular mechanismof glucocorticoid action. Postępy Hig. Med. Dośw., 2010; 64: 133-145
  Google Scholar
• 34. Penesová A., Rádiková Z., Vlček M., Kerlik J., Lukáč J., RovenskýJ., Imrich R.: Chronic inflammation and low-dose glucocorticoid effectson glucose metabolism in premenopausal females with rheumatoidarthritis free of conventional metabolic risk factors. Physiol.Res., 2013; 62: 75-83
  Google Scholar
• 35. Roberts A. James J. Dhatariya K.: Joint British Diabetes Societies(JBDS) for inpatient care group. Management of hyperglycaemiaand steroid (glucocorticoid) therapy. www.diabetologists-abcd. org.uk/JBDS.htm (10.2014)
  Google Scholar
• 36. Simmons L.R., Molyneaux L., Yue D.K., Chua E.L.: Steroid-induceddiabetes: is it just unmasking of type 2 diabetes? ISRN Endocrinol.,2012; 2012: 910905
  Google Scholar
• 37. Smolen J.S., Landewé R., Breedveld F.C., Buch M., Burmester G.,Dougados M., Emery P., Gaujoux-Viala C., Gossec L., Nam J., RamiroS., Winthrop K., de Wit M., Aletaha D., Betteridge N. i wsp.: EULARrecommendations for the management of rheumatoid arthritis withsynthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis., 2014; 73: 492-509
  Google Scholar
• 38. Solomon D.H., Love T.J., Canning C. Schneeweiss S.: Risk of diabetesamong patients with rheumatoid arthritis, psoriatic arthritisand psoriasis. Ann. Rheum. Dis., 2010; 69: 2114-2117
  Google Scholar
• 39. Svenson K.L., Lundqvist G., Wide L., Hällgren R.: Impaired glucosehandling in active rheumatoid arthritis: effects of corticosteroidsand antirheumatic treatment. Metabolism, 1987; 36: 944-948
  Google Scholar
• 40. Svenson K.L., Pollare T., Lithell H., Hällgren R.: Impaired glucosehandling in active rheumatoid arthritis: relationship to peripheralinsulin resistance. Metabolism, 1988; 37: 125-130
  Google Scholar
• 41. Tamez-Pérez H.E., Quintanilla-Flores D.L., Rodríguez-GutiérrezR., González-González J.G., Tamez-Peña A.L.: Steroid hyperglycemia:Prevalence, early detection and therapeutic recommendations: a narrativereview. World J. Diabetes, 2015; 6: 1073-1081
  Google Scholar
• 42. Umpierrez G.E., Hellman R., Korytkowski M.T., Kosiborod M.,Maynard G.A., Montori V.M., Seley J.J., Van den Berghe G.: EndocrineSociety: Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab., 2012; 97: 16-38
  Google Scholar
• 43. van der Goes M.C., Jacobs J.W., Boers M., Andrews T., BlomBakkersM.A., Buttgereit F., Caeyers N., Choy E.H., Cutolo M., DaSilva J.A., Guillevin L., Holland M., Kirwan J.R., Rovensky J., Saag K.G.i wsp.: Patient and rheumatologist perspectives on glucocorticoids:an exercise to improve the implementation of the European LeagueAgainst Rheumatism (EULAR) recommendations on the managementof systemic glucocorticoid therapy in rheumatic diseases. Ann.Rheum. Dis., 2010; 69: 1015-1021
  Google Scholar
• 44. van Everdingen A.A., Jacobs J.W., Siewertsz Van Reesema D.R.,Bijlsma J.W.: Low-dose prednisone therapy for patients with earlyactive rheumatoid arthritis: clinical efficacy, disease-modifyingproperties, and side effects: a randomized, double-blind, placebocontrolledclinical trial. Ann. Intern. Med., 2002; 136: 1-12
  Google Scholar
• 45. van Raalte D.H., Brands M., van der Zijl N.J., Muskiet M.H., PouwelsP.J., Ackermans M.T., Sauerwein H.P., Serlie M.J., Diamant M.:Low-dose glucocorticoid treatment affects multiple aspects of intermediarymetabolism in healthy humans: a randomised controlledtrial. Diabetologia, 2011; 54: 2103-2112
  Google Scholar
• 46. van Raalte D.H., Nofrate V., Bunck M.C., van Iersel T., ElassaissSchaap J., Nässander U.K., Heine R.J., Mari A., Dokter W.H., DiamantM.: Acute and 2-week exposure to prednisolone impair differentaspects of β-cell function in healthy men. Eur. J. Endocrinol., 2010;162: 729-735
  Google Scholar
• 47. van Raalte D.H., Ouwens D.M., Diamant M.: Novel insights intoglucocorticoid-mediated diabetogenic effects: towards expansion oftherapeutic options? Eur. J. Clin. Invest., 2009; 39: 81-93
  Google Scholar
• 48. Wassenberg S., Rau R., Steinfeld P., Zeidler H.: Very low-doseprednisolone in early rheumatoid arthritis retards radiographicprogression over two years: a multicenter, double-blind, placebocontrolledtrial. Arthritis Rheum., 2005; 52: 3371-3380
  Google Scholar
• 49. Yuen K.C., McDaniel P.A., Riddle M.C.: Twenty-four-hour profilesof plasma glucose, insulin, C-peptide and free fatty acid in subjectswith varying degrees of glucose tolerance following short-term,medium-dose prednisone (20 mg/day) treatment: evidence for differingeffects on insulin secretion and action. Clin. Endocrinol.,2012; 77: 224-232
  Google Scholar

Full text